The Indian pharmaceutical market size is expected to grow to US$ 100 billion by 2025, driven by increasing consumer spending, rapid urbanisation, and raising healthcare insurance among others.
India exports drugs to over 200 countries due to which pharmaceutical exports clocked a CAGR of 10.3 per cent to US$ 15.5 billion during 2014–15
Failure in international regulatory inspections is continuously tarnishing India’s reputation as a producer of high quality, low cost medicines. Also over the past couple of years the Indian Pharma companies have faced increased scrutiny from the regulators bringing a total of 11 warning letters being issued by the US regulator in 2015.
CPhI is glad to announce its 5th Annual Global Pharma Regulatory Summit which aims at bringing expert regulators across the globe who will share their knowledge on how to comply with regulatory guidelines for manufacturing and export quality drugs.
RiSiKo Consulting LLP has been actively involved in Pharma & Nutra Industry through various Strategic & Turnaround Advisory, RiSk management, Compliance Management, Transaction Structuring Advisory and has experience of working in various Pharma Business Environment existing in India,Dubai,USA,CIS, Europe, GCC,China, Mexico, Africa,SEA Region.
For further details on the events , please click below link :-
5th Annual Global Pharma Regulatory Summit 2016
RiSiKo believes in continuous Compliance,Process & Performance Improvement in Pharma & Nutra industry and has been part of similar events.
To know further about RiSiKo Consulting LLP & its services across globe , please visit out website :- www.risikollp.com